<DOC>
	<DOC>NCT02311881</DOC>
	<brief_summary>The purpose of the study is to determine whether paracetamol 1000 mg sustained-release (SR) tablets administered orally, twice daily are effective and safe in the treatment of patients with osteoarthritis of the knee or hip.</brief_summary>
	<brief_title>A 12-Week Efficacy Study of Paracetamol 1000mg Sustained-release Tablets in Patients With Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Male or female participants between 40 and 80 years of age Diagnosis of moderate to moderatelysevere osteoarthritis (OA) of either the knee or hip with respect to the following: Pain in one knee/hip over 3 months immediately before screening visit Use of non steroidal antiinflammatory drugs (NSAIDs), acetaminophen (paracetamol) or any other analgesic for 3 or more days per week for at least 3 months prior to screening visit Clinical diagnosis of osteoarthritis of knee/hip for minimum 6 month duration prior to screening visit Therapeutic benefit with acetaminophen use with a score of ≥ 1 on 5point categorical scale Radiological evidence of ≥ Grade 2 osteoarthritis according to KellgrenLawrence radiographic criteria Increased WOMAC Pain Subscale score of at least 20 % following untreated runin period Moderate to moderatelysevere selfreported pain on a 5point categorical scale following untreated runin period Historical selfreported positive therapeutic benefit with paracetamol use for osteoarthritis pain relief History of surgery or major trauma to the study joint Clinically significant signs or symptoms of inflammation upon completion of runin period Required ongoing use of analgesic therapy for other indications, anticoagulants, psychotherapeutic agents, aspirin at daily doses greater than 325 mg, statinclass hypolipidemic agents at doses that have not been stabilized, or other treatments know to interfere with pain perception History of hepatic or renal or liver or biliary disease or gastrointestinal surgery Participants with alanine aminotransferase (ALT) &gt;2 times Upper Limit Normal (2xULN) and bilirubin &gt; 1.5 times Upper Limit Normal (1.5xULN) (However, if direct bilirubin is &lt;35% and fractioned, isolated bilirubin &gt;1.5xULN is acceptable) Other arthritis type, fibromyalgia or collagen vascular disease or secondary OA of study joint or chronic pain condition</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>